Protective effect of mycophenolate mofetil on endothelial function in an aortic allograft model

Transplantation. 2011 Jan 15;91(1):35-41. doi: 10.1097/TP.0b013e3181fe12d6.

Abstract

Background: Whether mycophenolate mofetil (MMF) can prevent the vascular endothelial dysfunction related to the administration of calcineurin inhibitor after organ transplantation remains unknown.

Methods: Four groups of Lewis rats, grafted with Brown Norway donor aortic abdominal allograft, received since the transplantation cyclosporine A (CsA, 5 mg/kg/day), MMF (40 mg/kg/day), CsA+MMF, or vehicle (control) for 2 weeks.

Results: Fifteen days after transplantation, all immunosuppressive regimens were equally effective in preventing graft rejection. When compared with control rats, the endothelium-dependent relaxation to acetylcholine was reduced, and the vasoconstrictor effect of phenylephrine was enhanced in thoracic aorta of CsA-treated rats but not in rats treated with MMF alone or combined with CsA without difference for the endothelium-independent relaxation to sodium nitroprusside. The relaxation to acetylcholine was abolished by the nitric oxide (NO)-synthase inhibitor N-nitro-l-arginine in all groups. Moreover, the endothelial NO-synthase protein dimer:monomer ratio in the thoracic aorta and the plasma nitrites concentrations, an indicator of NO availability, were decreased in CsA-treated rats but not in rats treated with MMF alone or combined with CsA.

Conclusions: This study demonstrates that MMF prevents systemic endothelial dysfunction and the enhanced sensitivity to vasoconstrictors related to CsA administration in a rat allograft aortic model through an increase in NO availability related to the improvement of endothelial NO-synthase functionality.

MeSH terms

  • Animals
  • Aorta, Abdominal / transplantation*
  • Cyclic N-Oxides / pharmacology
  • Cyclosporine / therapeutic use*
  • Drug Therapy, Combination
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / physiology
  • Graft Rejection / drug therapy*
  • Immunosuppressive Agents / therapeutic use*
  • Male
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitrites / blood
  • Nitroarginine / pharmacology
  • Nitroprusside / pharmacology
  • Rats
  • Rats, Inbred BN
  • Rats, Inbred Lew
  • Spin Labels
  • Treatment Outcome
  • Vasodilation / drug effects

Substances

  • Cyclic N-Oxides
  • Immunosuppressive Agents
  • Nitrites
  • Spin Labels
  • Nitroprusside
  • Nitroarginine
  • Cyclosporine
  • Nitric Oxide Synthase
  • Mycophenolic Acid
  • tempol